Q-omics provides the consensus-scored ZNF438 profile across patient tissues and cancer cell-line models. ZNF438 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZNF438 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZNF438 RNA expression shows 19,216 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, THCA, and UVM as cancer lineages where ZNF438 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF438 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF438 survival associations across molecular data types. ZNF438 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF438 RNA expression–survival associations across cancer types. High ZNF438 expression shows unfavorable associations in LIHC, but favorable associations in SKCM, KIRC, LGG, HNSC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZNF438 RNA expression.
This table summarizes ZNF438 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF438. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF438 shows lower tumor expression in THCA, LUAD, BLCA, KICH and UCEC and higher tumor expression in KIRC. The THCA box plot shows higher ZNF438 RNA expression in normal versus tumor tissue (log2 FC = −1.071, t-test p < 0.001).
This table shows molecular features associated with ZNF438 in patient tissues and cancer cell lines. In patient samples, ZNF438 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF438 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
